Company news
Atara Biotherapeutics, Inc. news in 2024
Atara Biotherapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
November 11, 2024
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
November 4, 2024
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 3, 2024
Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Atara Biotherapeutics Announces $36 Million Registered Direct Offering
September 2, 2024
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
August 11, 2024
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 6, 2024
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
July 2, 2024
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
June 20, 2024
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
June 16, 2024
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
May 28, 2024
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
May 19, 2024
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
May 8, 2024
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
March 27, 2024
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 28, 2024
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 27, 2024
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
February 13, 2024
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
January 30, 2024
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 7, 2024
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 7, 2024
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
Decks in 2024
- Q3 2024 Earnings Presentation
Earnings · 32 slides · Nov 12, 2024
- H.C. Wainwright 26th Annual Global Investment Conference (September 2024)
Conference · 22 slides · Sep 9, 2024
- 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
Conference · 18 slides · Jan 8, 2024